Calcitonin gene related peptide in migraine: Current therapeutics, future implications and potential off-target effects

Jason Charles Ray*, Mahima Kapoor, Richard J. Stark, Shuu Jiun Wang, Lars Bendtsen, Manjit Matharu, Elspeth Jane Hutton

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.

Original languageEnglish
Article number324674
Pages (from-to)1325-1334
Number of pages10
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume92
DOIs
StatePublished - Nov 2021

Keywords

  • drug trials
  • headache
  • migraine

Fingerprint

Dive into the research topics of 'Calcitonin gene related peptide in migraine: Current therapeutics, future implications and potential off-target effects'. Together they form a unique fingerprint.

Cite this